Psychiatric events rare with Champix

Adverse neuropsychiatric events are rare with quit-smoking drug varenicline (Champix), and mostly limited to people with previous mental health problems, a study suggests.

Reviewing data on almost 22,000 US soldiers, researchers found no difference in rates of neuropsychiatric hospitalisations between those prescribed varenicline or nicotine-replacement therapy.

There were just 23 such hospitalisations among 10,814 varenicline users — 18 of whom had